From a pathological perspective, inactivating mutations in TET genes, mainly TET2, frequently occur in various cancers, including haematopoietic malignancies of bone marrow and the lymphatic system and some solid tumours (breast and colorectal cancer) [9–13]. This evidence concerns the gene TET2 and colorectal cancer.